Enterprise Value
0.00
Cash
0.00
Avg Qtr Burn
N/A
Short % of Float
2.40%
Insider Ownership
59.01%
Institutional Own.
0.44%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Tinlarebant (LBS-008) Details Dry eye disease , Age-related macular degeneration, Macular degeneration, Geographic atrophy | Phase 3 Data readout | |
Tinlarebant (LBS-008) Details Stargardt disease | Phase 3 Data readout | |
Tinlarebant (LBS-008) Details Stargardt disease | Phase 2/3 Data readout |